



Management of Cardiovascular Disease Risk in Rheumatoid Arthritis

Guest Editors:

Prof. Dr. Patrick H.M.C. Dessein

1. Departments of Medicine and Physiology, University of Witwatersrand, Johannesburg, South Africa
2. Rheumatology Unit, Free University Hospital, Faculty of Medicine and Pharmacy, Free University, Brussels, Belgium

Prof. Dr. Miguel Angel Gonzalez-Gay

1. Head of Rheumatology Department, Hospital Universitario Marqués de Valdecilla de Santander, 39008 Santander, Cantabria, Spain
2. Department of Medicine, Universidad de Cantabria, 39005 Santander, Cantabria, Spain

Deadline for manuscript submissions:

closed (15 December 2021)

Message from the Guest Editors

Dear Colleagues,

Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes mainly joint damage and increases the risk of cardiovascular disease (CVD) to a similar extent as diabetes. CVD in RA patients is associated with adverse traditional cardiovascular risk factor profiles, systemic inflammation, and their interactions, as well as genetic components. Additionally, medications used to treat disease activity, as well as population origin, impact CVD risk in RA patients. The increased atherogenesis that is experienced by RA patients awaits further elucidation. CVD risk assessment and prevention are currently suboptimal in RA patients.

This Special Issue aims to improve CVD risk management in the presence of RA. We therefore invite original basic science and clinical papers, meta-analyses, and state-of-the-art reviews that deal with atherogenic mechanisms, cardiovascular risk stratification, and the role of lifestyle modification, cardiovascular drugs, and antirheumatic agents in reducing CVD risk in RA patients.

Prof. Dr. Patrick H.M.C. Dessein

Prof. Dr. Miguel Angel Gonzalez-Gay

Guest Editors





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care
Medicine, University of Tokyo,
Tokyo, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)